Perjeta Among Biosimilar Targets As Viatris Insists It Can ‘Do A Lot More’
Viatris Has Identified 13 New Biosimilar Targets For Development
At Viatris’ inaugural investor day, management spoke at length about the company’s ambitions for biosimilars, underlining that the company currently had no plans to expand its manufacturing footprint at the present time.
You may also be interested in...
Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.
Viatris’ share price closed the day nearly 15% down after announcing weaker than anticipated revenue, adjusted EBITDA and cash flow guidance for 2021. The market reacted strongly to the company’s expectations and ambitions, with management continuing to stress the strength of the combined Mylan and Upjohn businesses.